[A Case of Metastatic Renal Cancer Responding to Sunitinib as the Eighth Line Therapy].

A 62-year-old male presenting with gross hematuria and right renal mass was referred to our Urology Department. Computed tomography revealed a right renal mass, with multiple pulmonary lesions. He underwent right nephrectomy for highly suspected renal cell carcinoma with pulmonary metastases (cT3aN0M1). The pathological diagnosis was clear cell renal cell carcinoma, pT1b. Following surgery, he was treated with multiple regimens of chemotherapy, ranging from interferon alpha, multiple tyrosine kinase inhibitors such as sorafenib, axitinib, pazopanib and cabozantinib, everolimus, and nivolumab, all of which were discontinued after its induction, either due to adverse events or progressive disease. He was finally administered Sunitinib as the 8th line "last-ditch" treatment, which resulted in significant tumor shrinkage. No disease progression has been observed 25 months after initiating sunitinib administration.

[A Case of Strangulated Bowel Obstruction Caused by Barbed Suture Following Laparoscopic Sacrocolpopexy].

A 63-year-old woman underwent laparoscopic sacrocolpopexy for pelvic organ prolapse. Four days postoperatively, she underwent an abdominal computed tomography scan because she developed a stomachache, and a strangulated bowel obstruction was suspected. The patient then underwent an emergency laparotomy which revealed strangulation of the small intestine caused by a band formed between the stump of a barbed suture and the mesentery. The strangulation was released by resecting the stump, and intestinal resection was not necessary. Nine days following the re-intervention, the patient was discharged from our hospital. As of four months after the surgery, she has not experienced any recurrence of pelvic organ prolapse or other postoperative complications. We need some ingenuity when using barbed suture in situations where the thread and the intestine come into contact.

[A Case of Advanced Bladder Carcinoma Treated by Third-Line Gemcitabine and Paclitaxel Chemotherapy].

A 77-year-old man underwent robot-assisted laparoscopic radical cystectomy with pelvic lymph node dissection and ileal conduit for bladder carcinoma. Six months postoperatively, multiple lung metastases and a sacral bone metastasis were detected on computed tomography (CT). The patient then received gemcitabine-carboplatin (G-CBDCA) because he had renal dysfunction, which is a contraindication for cisplatin. After two courses of G-CBDCA, pembrolizumab was started because the lung metastases showed progression. The patient then underwent gemcitabine-paclitaxel (GP) chemotherapy (G : 1,000 mg/m² on days 1, 8, and 15 ; P : 180 mg/m² on day 1 ; every 4 weeks) as third-line treatment because of further progression after two courses of pembrolizumab. The lung metastases showed an almost complete response after two courses of GP. Additionally, after two courses, the lung metastases showed a complete response, and no abnormal fluorodeoxyglucose uptake in the sacral bone metastasis was seen on positron emission tomography-CT. The patient suffered neutropenia and anemia as adverse effects ; however, these disappeared after discontinuing gemcitabine. Chemotherapy was discontinued after the four courses in accordance with the patient's wishes, and he has remained free from recurrence for 2 months after discontinuing therapy.